title: Oncolytic virotherapy using herpes simplex virus: how far have we come?
abstract: Oncolytic virotherapy exploits the properties of human viruses to naturally cytolysis of cancer cells. The human pathogen herpes simplex virus (HSV) has proven particularly amenable for use in oncolytic virotherapy. The relative safety of HSV coupled with extensive knowledge on how HSV interacts with the host has provided a platform for manipulating HSV to enhance the targeting and killing of human cancer cells. This has culminated in the approval of talimogene laherparepvec for the treatment of melanoma. This review focuses on the development of HSV as an oncolytic virus and where the field is likely to head in the future.
authors: Centre for Virus Research, Westmead Millennium Institute for Medical Research, The University of Sydney, NSW, Australia.
authors: Nicolas As
authors: NA
authors: Sokolowski
authors: Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW, Australia.
authors: Helen
authors: H
authors: Rizos
authors: Centre for Virus Research, Westmead Millennium Institute for Medical Research, The University of Sydney, NSW, Australia.
authors: Russell J
authors: RJ
authors: Diefenbach
keywords: cancer; combination therapy; herpes simplex virus; immunity; oncolysis